Company Overview and News
WCT announced that it has been awarded a RM1.77bil contract to build nine blocks of office towers, and three blocks of serviced apartments along with podium block at the Pavilion Damansara Heights project.
5347 TNABY 9679 5196 TNABF 7167
2018-09-19 theedgemarkets - 1
KUALA LUMPUR (Sept 19): Maybank Kim Eng analyst Kevin Wong upgraded the recommendation on Berjaya Food Bhd to buy from hold.
KUALA LUMPUR (Sept 19): CIMB IB Research has maintained its “Hold” rating on Berjaya Food Bhd (BFood)at RM1.39 with a lower target price of RM1.44 (from RM1.74) and said BFood’s 1QFY19 core net profit of RM6.2 million was below house and market consensus expectations, mainly due to lower-than-expected KRR earnings.
KUALA LUMPUR (Sept 19): The FBM KLCI is expected to trade range bound today and rise higher on some bargain hunting activities in line with the overnight gains at most global markets.
4863 7235 5196 MYTEF 5202 0162 3484
KUALA LUMPUR: Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Sept 19) may include the following: FGV Holdings Bhd, MSM Malaysia Holdings Bhd, Ideal Jacobs (M) Corp Bhd, Berjaya Food Bhd, Vizione Holdings Bhd, WCT Bhd, Damansara Realty Bhd, YFG Bhd, Telekom Malaysia Bhd, Superlon Holdings Bhd, MMAG Holdings Bhd and PanPages Bhd.
4863 7235 9679 5196 MYTEF 5041 5202 0162 BSMAF 7099 1818 3484
KUALA LUMPUR (Sept 18): Berjaya Food Bhd (BFood), which operates the Starbucks Coffee chain in Malaysia and Brunei, the Kenny Rogers Roasters (KRR) chain in Malaysia and Jollibean in Singapore, saw its net profit rise 16.9% to RM6.24 million in the first financial quarter ended July 31, 2018 (1QFY19) from RM5.34 million a year ago, on higher profit contributions from Starbucks operations in tandem with the higher revenue achieved.
5196 BSMAF 1818
Berjaya Food Bhd (Sept 4, RM1.40) Maintain buy with a lower fair value (FV) of RM2.01: We maintain our “buy” call on Berjaya Food Bhd (BFood) with a lower FV of RM2.01 (from RM2.17) after trimming financial year 2019 (FY19) and FY20 earnings forecasts by 22% and 29%, respectively. We have factored in lower margin assumptions and higher gestation costs.
KUALA LUMPUR, Aug 15 — Berjaya Food (BFood) Bhd will further cement its presence in the Indian market with the opening of 30 Kenny Rogers Roasters (KRR) restaurants and 75 Jollibean kiosks through its development agent, World Iconic Brand (WIB) Hospitality Pvt Ltd India.
KUALA LUMPUR (Aug 15): Berjaya Food Bhd (BFood) will be opening at least 30 more Kenny Rogers Roasters (KRR) outlets and 75 Jollibean kiosks in India, via a partnership with World Iconic Brands (WIB) Hospitality Private Ltd inked today.
KUALA LUMPUR (July 4): The outlook for the local equity market looks positive for the next twelve to eighteen months, backed by steady economic growth, according to AmInvestment Bank Research.
5258 PBLOF 5196 7237 1295
Berjaya Food Bhd (June 22, RM1.62) Maintain hold with a lower target price of RM1.74: Berjaya Food Bhd (BFood) reported a turnover of RM160 million, up 5.7% year-on-year (y-o-y), while core net profit surged 50% y-o-y to RM2.4 million for its fourth quarter of financial year 2018 (4QFY18). This brought its full-year FY18 core net profit to RM19.3 million — after stripping out one-off RM15.3 million loss from the disposal of Kenny Rogers Roasters (KRR) Indonesia — which disappointed both our and Bloomberg consensus expectations, at 93% and 87% of the respective forecasts.
KUALA LUMPUR (June 22): CIMB Research said today Berjaya Food Bhd's Starbucks operations in Malaysia will continue to sustain Berjaya Food's earnings growth on expectation of 25 to 30 Starbucks outlets to be opened per year.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...